Claims for Patent: 9,919,048

Summary for Patent: 9,919,048

Title:	Targeting of interleukin-1 and -18 signaling in treatment of septic shock
Abstract:	The present invention relates to the inactivation of interleukin-1 and interleukin-18 signaling in treatment of inflammation and septic shock. More specifically, it relates to a sequential or simultaneous application of both an interleukin-1 receptor antagonist and an interleukin-18 antibody. In one preferred embodiment, a combination treatment of an IL-1 receptor antagonist and an IL-18 antibody is used.
Inventor(s):	Vandenabeele; Peter (Sint-Amandsberg, BE), Cauwels; Anje (Merelbeke, BE), Vandenberghe; Tom (Haasdonk, BE)
Assignee:	VIB VZW (Ghent, BE) UNIVERSITEIT GENT (Ghent, BE)
Application Number:	15/111,374
Patent Claims:	1. A method of treating sepsis comprising administering an interleukin-1 receptor antagonist and an interleukin-18 antibody to a subject in need thereof. 2. The method of claim 1, wherein the interleukin-1 receptor antagonist and the interleukin-18 antibody are administered to the subject simultaneously. 3. The method of claim 1, wherein the interleukin-1 receptor antagonist and the interleukin-18 antibody are administered to the subject sequentially. 4. The method of claim 1, wherein said interleukin-1 receptor antagonist is recombinant, non-glycosylated Anakinra. 5. The method of claim 1, wherein said interleukin-1 receptor antagonist is an interleukin-1 receptor antibody. 6. The method of claim 1, wherein said interleukin-1 receptor antagonist neutralizes interleukin-1 receptor. 7. The method of claim 1, wherein said interleukin-18 antibody neutralizes interleukin-18. 8. A method of therapeutically treating sepsis comprising administering an interleukin-1 receptor antagonist and an interleukin-18 antibody to a subject in need thereof. 9. A method of prophylactically treating sepsis comprising administering an interleukin-1 receptor antagonist and an interleukin-18 antibody to a subject in need thereof. 10. The method of claim 8, wherein the interleukin-1 receptor antagonist and the interleukin-18 antibody are administered simultaneously. 11. The method of claim 8, wherein the interleukin-1 receptor antagonist and the interleukin-18 antibody are administered sequentially. 12. The method of claim 11, wherein administration of the interleukin-1 receptor antagonist and administration of the interleukin-18 antibody is separated by a maximum time period of 5 hours. 13. The method of claim 11, wherein administration of the interleukin-1 receptor antagonist and administration of the interleukin-18 antibody is separated by a maximum time period of 4 hours. 14. The method of claim 11, wherein administration of the interleukin-1 receptor antagonist and administration of the interleukin-18 antibody is separated by a maximum time period of 3 hours. 15. The method of claim 11, wherein administration of the interleukin-1 receptor antagonist and administration of the interleukin-18 antibody is separated by a maximum time period of 2 hours. 16. The method of claim 11, wherein administration of the interleukin-1 receptor antagonist and administration of the interleukin-18 antibody is separated by a maximum time period of 1 hour. 17. The method of claim 11, wherein the interleukin-1 receptor antagonist and the interleukin-18 antibody are administered directly one after the other.

Details for Patent 9,919,048

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	KINERET	anakinra	Injection	103950	11/14/2001		2034-01-21